Janssen (J&J) Reports Voting Results from FDA Advisory Committees for Spravato (esketamine) in Adults with Resistant Depression

 Janssen (J&J) Reports Voting Results from FDA Advisory Committees for Spravato (esketamine) in Adults with Resistant Depression

Janssen (J&J) Reports Voting Results from FDA Advisory Committees for Spravato (esketamine) in Adults with Resistant Depression

Shots:

  • FDA’s PDAC & DSaRM has jointly voted (14 yes, 2 no, 1 abstain) for favorable benefit-risk profile of Spravato (esketamine) nasal spray C-III, based on five P-III studies (including three short term, one maintenance and a long-term study) vs PBO in patients with treatment-resistant depression
  • The study demonstrated no new safety signals with well tolerated results, providing support for its NDA filling to the US FDA on 4 Sept,2018, with its expected PDUFA date on 4 Mar,2019
  • Spravato (esketamine) is a glutamate receptor modulator nasal spray, used for restoring synaptic connections in the brain cells in major depressive disorders and has received FDA’s BT designation for treatment-resistant depression with imminent risk for suicide

Click here to read full press release/ article | Ref: J&J | Image: UNI-Learning

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post